NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
NRx Pharmaceuticals, Inc.’s vaccine candidate BriLife has garnered initial positive Phase II data in COVID-19, pushing the firm to begin a registrational study pending an independent review.
While the data are early, if the full cohort of patients demonstrates outcomes comparable to the initial subgroup, this could indicate potential vaccine effectiveness
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
